Zeimet AG - Search Results

1

A comparison of four technologies for detecting p53 aggregates in ovarian cancer.

Heinzl N, Koziel K, Maritschnegg E, Berger A, Pechriggl E, Fiegl H, Zeimet AG, Marth C, Zeillinger R, Concin N. Heinzl N, et al. Among authors: zeimet ag. Front Oncol. 2022 Sep 8;12:976725. doi: 10.3389/fonc.2022.976725. eCollection 2022. Front Oncol. 2022. PMID: 36158680 Free PMC article.

2

[Prognostic significance of tumor markers in cervix cancer].

Marth C, Zeimet AG, Fuith LC, Hetzel H, Zech S, Daxenbichler G. Marth C, et al. Among authors: zeimet ag. Gynakol Geburtshilfliche Rundsch. 1992;32 Suppl 1:114. doi: 10.1159/000271963. Gynakol Geburtshilfliche Rundsch. 1992. PMID: 1286307 German. No abstract available.

3

[Interferon-gamma suppresses expression of the HER-2 oncogene in ovarian cancer cells].

Marth C, Müller-Holzner E, Zeimet AG, Greiter E, Cronauer MV, Doppler W, Eibl B, Hynes NE, Daxenbichler G. Marth C, et al. Among authors: zeimet ag. Gynakol Geburtshilfliche Rundsch. 1992;32(1):31-4. doi: 10.1159/000271830. Gynakol Geburtshilfliche Rundsch. 1992. PMID: 1355379 German.

4

Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells.

Marth C, Lang T, Cronauer MV, Doppler W, Zeimet AG, Bachmair F, Ullrich A, Daxenbichler G. Marth C, et al. Among authors: zeimet ag. Int J Cancer. 1992 Sep 9;52(2):311-6. doi: 10.1002/ijc.2910520226. Int J Cancer. 1992. PMID: 1355758

5

Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells.

Marth C, Zeimet AG, Böck G, Daxenbichler G. Marth C, et al. Among authors: zeimet ag. Eur J Cancer. 1992;28A(12):2002-6. doi: 10.1016/0959-8049(92)90248-z. Eur J Cancer. 1992. PMID: 1419298

6

Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells.

Marth C, Müller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppler W, Eibl B, Hynes NE, Daxenbichler G. Marth C, et al. Among authors: zeimet ag. Cancer Res. 1990 Nov 1;50(21):7037-41. Cancer Res. 1990. PMID: 2119884

7

Distribution of CA 125 in placental tissues.

Fuith LC, Müller-Holzner E, Marth C, Perkmann E, Zeimet A, Daxenbichler G. Fuith LC, et al. Int J Biol Markers. 1989 Apr-Jun;4(2):78-80. doi: 10.1177/172460088900400203. Int J Biol Markers. 1989. PMID: 2768891

8

Increased production of immune activation marker neopterin by colony-stimulating factors in gynecological cancer patients.

Marth C, Weiss G, Koza A, Reibnegger G, Daxenbichler G, Zeimet AG, Fuchs D, Wachter H, Dapunt O. Marth C, et al. Among authors: zeimet ag. Int J Cancer. 1994 Jul 1;58(1):20-3. doi: 10.1002/ijc.2910580105. Int J Cancer. 1994. PMID: 7516925 Clinical Trial.

9

Prognostic value of CD44 splice variant expression in ovarian cancer.

Uhl-Steidl M, Müller-Holzner E, Zeimet AG, Adolf GR, Daxenbichler G, Marth C, Dapunt O. Uhl-Steidl M, et al. Among authors: zeimet ag. Oncology. 1995 Sep-Oct;52(5):400-6. doi: 10.1159/000227497. Oncology. 1995. PMID: 7543667

10

Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases.

Müller-Holzner E, Zeimet AG, Daxenbichler G, Marth C, Müller LC, Dapunt O. Müller-Holzner E, et al. Among authors: zeimet ag. Breast Cancer Res Treat. 1993;25(1):47-55. doi: 10.1007/BF00662400. Breast Cancer Res Treat. 1993. PMID: 7686056

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters